Understanding and circumventing resistance to anticancer monoclonal antibodies
- 1 May 2009
- journal article
- review article
- Published by Taylor & Francis Ltd in mAbs
- Vol. 1 (3), 222-229
- https://doi.org/10.4161/mabs.1.3.8292
Abstract
With the widespread use of therapeutic monoclonal antibodies in the treatment of patients with cancer, resistance to these agents has become a major issue. Preclinical models of drug action or resistance have contributed to unravel the main mechanisms of resistance, involving both tumor-associated and host related factors. However our understanding of how a monoclonal antibody destroys cancer cells in a patient and why it one day stops being effective are still far from being complete. This review focuses on the available data on mechanisms of action and resistance to rituximab and includes some additional information for other monoclonal antibodies. Innovative approaches designed to overcome resistance, such as combination immunotherapy, costimulation with cytokines or growth factors are presented.Keywords
This publication has 96 references indexed in Scilit:
- Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survivalBlood, 2009
- Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer CellsClinical Cancer Research, 2009
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235Cancer Research, 2008
- A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular LymphomaClinical Cancer Research, 2008
- Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabCancer, 2008
- Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer CellsClinical Cancer Research, 2008
- The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximabLeukemia, 2008
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersOncogene, 2008
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI Journal of the National Cancer Institute, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004